US Biological, Akrivis to Co-develop Research Products | GenomeWeb

NEW YORK (GenomeWeb News) – Akrivis Technologies today said that it has inked an agreement with United States Biological to co-develop, manufacture, and sell research products based on Akrivis' Z-Tect technology.

The Z-Tect technology is a nanotechnology-based technique for detecting unusually low levels of protein and molecular targets. According to the firms, the technology has "ultra-low limits of detection several thousand fold lower than currently achievable," and will make it possible to "vastly improve the early detection of cancer biomarkers in vitro."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

Oct
13
Sponsored by
Personal Genome Diagnostics

This online seminar will discuss sample collection challenges associated with tumor sequencing, with a particular focus on somatic variant testing in plasma.